Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, today announced that they presented data from a Phase I clinical trial of their anti-cancer compound, DTS-201, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA.

DTS-201 is a doxorubicin prodrug developed for the targeted treatment of several solid cancers, including chemo-resistant tumors. The product is activated by enzymes specific to the tumor environment. During its Phase I clinical trial, DTS-201 was shown to be well tolerated and able to deliver high doses of free doxorubicin in humans.

The purpose of the DTS-201 Phase I clinical study is to assess the product's Maximum Tolerated Dose (MTD), safety profile and pharmacokinetic profile in patients with advanced or metastatic solid tumors. In a poster presentation entitled "Results of a Phase I study of DTS-201, a peptidic prodrug of doxorubicin in patients with solid tumors (Abstract # 2547)", researchers concluded that:

-- DTS-201 was well tolerated by twenty-five cancer patients treated with doses of up to 400 mg/m2 every three weeks. This corresponds to 3.75 times the standard dose of doxorubicin;

-- DTS-201 was safe and well tolerated at cumulative doses of up to 2750 mg/m2;

-- Evidence of clinical efficacy was observed: two patients showed partial responses and three patients with chemo-resistant tumors showed disease stabilisation;

-- The recommended dose for Phase II clinical trials is 400 mg/m2.

The high levels of tolerance to the product and positive clinical responses observed during this Phase I trial strongly support an assessment of the efficacy of DTS-201 in a Phase II study.

"DTS-201 is a safe and active compound which allowed delivery of a high dose of doxorubicin with
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/3/2015)... , Aug. 3, 2015 Biosensors International ... SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer ... financial results for its first fiscal quarter ended ... Quarter Highlights and Recent Developments: ... improving its cost structure, driven by lower operating ...
(Date:8/3/2015)... 3, 2015 /OFF HOLD ... LLC, PIV757417 The following release: "Biotech Advancements Coupled ... Products & Treatments for Critical-Care Patients With Severe ... 3 Aug 2015 12:30 GMT Cooperative ... surgical research and top-tier universities for identifying biotech ...
(Date:8/3/2015)...  Array BioPharma Inc. (NASDAQ: ARRY ) ... full year of its fiscal year ended June ... of Array, noted, "Binimetinib and encorafenib, two innovative ... for regulatory submissions in 2016. Additional data shared ... colorectal cancer further validate the value of these ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... Heavy babies have more birth complications; they are also ... PORTLAND, Ore., Oct. 31 A study by ... 40,000 women and their,babies found that women who gained ... as likely to have a heavy baby. Published in,the ...
... Bulletin Board: VRML) announced today that it has ... Agreement between the parties,through October, 2009. This extension ... development and commercialization of two tests, OVA1(TM) and,VASCLIR(TM)., ... women with ovarian tumors that,are at high risk ...
Cached Medicine Technology:Gaining Too Much Weight During Pregnancy Nearly Doubles Risk of Having a Heavy Baby 2Gaining Too Much Weight During Pregnancy Nearly Doubles Risk of Having a Heavy Baby 3Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 2Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 3Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 4
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest healthcare ... lab testing and precision medicine solutions that can help pharmacists and other healthcare ... than 8.6 million adverse drug events are reported in the U.S. Pharmacogenetic ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... the largest online retailer of nutritional supplements, has officially opened the polls ... 11 awards in the following categories:, ,     Brand of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... Alachua, FL (PRWEB) , ... August 03, 2015 , ... ... peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, ... , A live webcast and subsequent archived replay of the Company’s presentation may be ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... Over 400 personnel of the Central Reserve Police Force (CRPF), ... to drugs and alcohol// , according to an internal survey. ... number of men who have become drug dependent and found ... ,He said the survey was started in February ...
... There appears to be no conclusive proof that ... researchers from the American Cancer Society//. This is ... ,Though many medical specialists still prescribe vitamins ... Jacobs, senior epidemiologist and vitamin specialist with the ...
... There is no need for a malaria hospital in Kolkata ... L Joshi, Director of National Vector Born Disease Control Programme. ... dengue and malaria, Joshi said last year in Kolkata only ... the corresponing year was 73., ,Reprentatives of UP, Bihar, ...
... patients who would have to fork out much less ... Merck and Pfizer losing// their patent on drugs commanding ... Ranbaxy and Dr Reddy's Laboratories are being touted as ... vacuum created by the patent expiry of two biggest ...
... for Genetic Engineering and Biotechnology (CIGB) has registered the ... production of an anti-hepatitis B vaccine. // ... a true world scientific breakthrough, and it was obtained ... process required for it. , ,At a press ...
... new study, men with prostate cancer are more influenced ... //from trusting on clinical trial evidences. ... and comparing the anecdotal experiences of others with prostate ... treatment options were entirely different from them are the ...
Cached Medicine News:Health News:Misconception on Treatment Options among Prostate Cancer Patients 2
Over 10,000 entries. This dictionary is both a home medical guide and as an aid for all those working in the medical and allied professions. The entries are laid out and jargon-free....
... Medical Spanish pocket plus for PDA is ... PDA and the Medical Spanish Dictionary pocket for ... plus for PDA provides an overview of the ... phrases, as well as basics of anatomy and ...
Taber's Cyclopedic Medical Dictionary is published by F.A. Davis. Contains approximately 56,000 terms....
This portable resource provides definitions for medical acronyms and abbreviations....
Medicine Products: